Disc Medicine’s Promising Position in MF Anemia Treatment: Buy Rating Affirmed by Evan Seigerman

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Disc Medicine (IRON – Research Report) and increased the price target to $120.00 from $112.00.

Evan Seigerman has given his Buy rating due to a combination of factors that highlight Disc Medicine’s promising position in addressing MF anemia. The recent KOL event underscored the significant need for new therapies, as a large percentage of patients treated with ruxolitinib experience anemia, leading to suboptimal dosing and treatment discontinuation. DISC-0974 stands out as a potential monotherapy or combination therapy with JAK inhibitors, offering a broader application beyond transfusion-dependent patients.
Additionally, the initial clinical data for DISC-0974, though early, shows competitive efficacy compared to existing treatments like luspatercept, especially in non-transfusion dependent patients. The company’s strategic focus on addressing the unmet needs in MF anemia, coupled with promising early clinical data and potential pivotal endpoints, supports a positive outlook for Disc Medicine’s stock. Furthermore, the company’s broader pipeline, including assets like Bitopertin, provides additional avenues for growth and value creation.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $118.00 price target.